USPTO serial 79212382
TOLERO PHARMACEUTICALS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 3, 2018
- Examiner
- FOSDICK, GEOFFREY A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TOLERO PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Sumitomo Dainippon Pharma Co., Ltd.
Osaka 541-0045, JP
Other trademarks owned by Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Osaka 541-0045, JP
Other trademarks owned by Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd.
Osaka 541-0045, JP
Other trademarks owned by Sumitomo Dainippon Pharma Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Howard N. Aronson
Howard N. Aronson Lackenbach Siegel LLP1 Chase Rd.Lackenbach Siegel Bldg.Scarsdale, NY 10583-4156Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the central nervous system, namely, diseases of the brain, movement, ocular motility and spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy and Parkinson's disease and central nervous systems infections; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the peripheral nervous system, namely, amyotrophic lateral sclerosis, numbness, lightheadedness, dysuria and dyshidrosis; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the urogenital system, namely, urological diseases, infertility, sexually transmitted diseases and inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the cardiovascular system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the metabolic system, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the renal system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the gastroenterological system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the ophthalmologic system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the dermatologic system, namely, dermatitis, eczema, psoriasis, skin pigmentation diseases and sexually transmitted diseases; pharmaceutical preparations for the prevention and treatment of hematologic and oncologic disorders and diseases; pharmaceutical preparations for the prevention and treatment of psychiatric disorders and diseases, namely, anxiety disorders, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Parkinson's disease, Alzheimer's disease, cerebral palsy, multiple sclerosis and seizures; pharmaceutical preparations for the prevention and treatment of allergic disorders and diseases and disorders and diseases of the immune system, namely, autoimmune diseases and immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of connective tissue and joints, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures and cartilage injuries; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for use in chemotherapy | SECTION 71 - CANCELLED | — |
| 044 | Providing medical information | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Sumitomo Dainippon Pharma Co., Ltd.
- Other trademarks owned by Sumitomo Dainippon Pharma Co., Ltd.
- Other trademarks owned by Sumitomo Dainippon Pharma Co., Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named TOLERO PHARMACEUTICALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 19, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Feb 28, 2026 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Feb 28, 2026 | INPC | INVALIDATION PROCESSED | — |
| Sep 17, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 17, 2025 | C71T | CANCELLED SECTION 71 | — |
| Jul 3, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 26, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 4, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 4, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 3, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 3, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 17, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 17, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 13, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Mar 28, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 28, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 28, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 15, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 14, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 13, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 13, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 22, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 19, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 15, 2017 | ALIE | ASSIGNED TO LIE | — |
| Dec 7, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 8, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 8, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 12, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 27, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 27, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 25, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 21, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 20, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 19, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 19, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 14, 2017 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 13, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |